PSAT1 Promotes NSCLC Progression via the De Novo Serine Synthesis Pathway and Represents a Therapeutic Vulnerability
Cancer Medicine · 2026
DOI: 10.1002/cam4.71780 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Medicine, 2026. Verfasst von Xijia Zhou und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory and Critical Care Medicine, the Second Hospital of Jilin University, Changchun, China. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Serine, Transaminases. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: "Medical+X" Cross Innovation Team "Unveiling and Leading" Construction Project, Disciplinary Crossing and Integration and Innovation Cultivation Project of Jilin University.
Abstract (Originalsprache)
Background
Non‐small cell lung cancer (NSCLC) is a malignant tumor characterized by high morbidity and mortality, as well as metabolic reprogramming. Enhanced serine synthesis plays a crucial role in the aberrant metabolism of NSCLC. Among the three key enzymes involved in serine synthesis, phosphoserine aminotransferase 1 ( PSAT1 ) requires further investigation to elucidate its regulatory mechanisms in NSCLC.
Methods
In this study, we employed bioinformatics analysis, immunohistochemistry, CCK‐8 assay, colony formation assay, flow cytometry assay, isotope tracing technique, WB analysis, and nude mouse xenograft models to validate the expression and function of PSAT1 in NSCLC.
Results
Our results demonstrated that PSAT1 was significantly upregulated in NSCLC cells and contributed to promoting cell proliferation, inhibiting apoptosis, and attenuating the efficacy of gefitinib treatment. Moreover, knockdown of PSAT1 led to inhibition of the de novo serine synthesis pathway (SSP), elevation of reactive oxygen species (ROS) levels, and activation of the mitochondrial apoptotic pathway. Notably, combined knockdown of PSAT1 with exogenous serine intake inhibition synergistically suppressed NSCLC progression.
Conclusion
Collectively, our findings highlight that PSAT1 serves as a biomarker for metabolic reprogramming in NSCLC and exhibits a close association with disease development and treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Respiratory and Critical Care Medicine, the Second Hospital of Jilin University, Changchun, China.
ORCID-Profile: Xijia Zhou
Förderung
- "Medical+X" Cross Innovation Team "Unveiling and Leading" Construction Project
- Disciplinary Crossing and Integration and Innovation Cultivation Project of Jilin University
Zitieren
APA
Zhou, X., Zhao, M., Cao, Y., Zhou, X., & Wang, K. (2026). PSAT1 Promotes NSCLC Progression via the De Novo Serine Synthesis Pathway and Represents a Therapeutic Vulnerability. Cancer Medicine. https://doi.org/10.1002/cam4.71780
Vancouver
Zhou X, Zhao M, Cao Y, Zhou X, Wang K. PSAT1 Promotes NSCLC Progression via the De Novo Serine Synthesis Pathway and Represents a Therapeutic Vulnerability. Cancer Medicine. 2026. doi:10.1002/cam4.71780
BibTeX
@article{Zhou2026,
author = {Zhou, Xijia and Zhao, Min and Cao, Yingshu and Zhou, Xiangyu and Wang, Ke},
title = {PSAT1 Promotes NSCLC Progression via the De Novo Serine Synthesis Pathway and Represents a Therapeutic Vulnerability},
journal = {Cancer Medicine},
year = {2026},
doi = {10.1002/cam4.71780}
}
EUVIMED